8-K - ORIC Pharmaceuticals, Inc. | StockGist

Current Report Details

Event Type

Financial Results

Impairment

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exc

Financial Results

2.05

Costs Associated with Exit or Disposal Activities. On August 12, 2025, the Company initiated a strategic pipeline prioritization to focus operational and financ

Impairment

$1.9M

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 12, 2025 104 Cover Page Interactive Data File (embedded

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1